2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Catapano, 2016, 2016 ESC/EAS Guidelines for the management of dyslipidaemias, Eur Heart J, 37, 2999, 10.1093/eurheartj/ehw272

Ference, 2017, Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel, Eur Heart J, 38, 2459, 10.1093/eurheartj/ehx144

Townsend, 2015, Cardiovascular disease in Europe--epidemiological update 2015, Eur Heart J, 36, 2696, 10.1093/eurheartj/ehv428

Cooney, 2009, SCORE Investigators. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies, Eur J Cardiovasc Prev Rehabil, 16, 541, 10.1097/HJR.0b013e32832b38a1

Global Status Report on Noncommunicable Diseases 2014

Cooney, 2009, Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians, J Am Coll Cardiol, 54, 1209, 10.1016/j.jacc.2009.07.020

Hajifathalian, 2015, A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys, Lancet Diabetes Endocrinol, 3, 339, 10.1016/S2213-8587(15)00081-9

Cooney, 2010, Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future?, Circulation, 122, 300, 10.1161/CIRCULATIONAHA.109.852756

Perk, 2012, European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts), Eur Heart J, 33, 1635, 10.1093/eurheartj/ehs092

Piepoli, 2016, 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), Eur Heart J, 37, 2315, 10.1093/eurheartj/ehw106

Cooney, 2016, Cardiovascular risk estimation in older persons: SCORE O.P, Eur J Prev Cardiol, 23, 1093, 10.1177/2047487315588390

Berry, 2012, Lifetime risks of cardiovascular disease, N Engl J Med, 366, 321, 10.1056/NEJMoa1012848

Foster, 2018, The effect of socioeconomic deprivation on the association between an extended measurement of unhealthy lifestyle factors and health outcomes: a prospective analysis of the UK Biobank cohort, Lancet Public Health, 3, e576, 10.1016/S2468-2667(18)30200-7

Kavousi, 2012, Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study, Ann Intern Med, 156, 438, 10.7326/0003-4819-156-6-201203200-00006

Vlachopoulos, 2015, The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society, Atherosclerosis, 241, 507, 10.1016/j.atherosclerosis.2015.05.007

Yeboah, 2012, Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals, JAMA, 308, 788, 10.1001/jama.2012.9624

Madsen, 2017, Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies, Eur Heart J, 38, 2478, 10.1093/eurheartj/ehx163

Mortensen, 2018, Statin trials, cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA, JACC Cardiovasc Imaging, 11, 221, 10.1016/j.jcmg.2017.01.029

Lin, 2018, Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force, JAMA, 320, 281, 10.1001/jama.2018.4242

Baber, 2015, Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study, J Am Coll Cardiol, 65, 1065, 10.1016/j.jacc.2015.01.017

McDermott, 2017, Plaque composition in the proximal superficial femoral artery and peripheral artery disease events, JACC Cardiovasc Imaging, 10, 1003, 10.1016/j.jcmg.2016.08.012

Sillesen, 2018, Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans, Eur Heart J Cardiovasc Imaging, 19, 1042, 10.1093/ehjci/jex239

Perrone-Filardi, 2011, Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology, Eur Heart J, 32, 1986, 10.1093/eurheartj/ehq235

Den Ruijter, 2012, Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis, JAMA, 308, 796, 10.1001/jama.2012.9630

Lorenz, 2010, Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS), Eur Heart J, 31, 2041, 10.1093/eurheartj/ehq189

Garg, 2018, Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: the Multi-Ethnic Study of Atherosclerosis (MESA), J Cardiovasc Comput Tomogr, 12, 493, 10.1016/j.jcct.2018.10.001

Hong, 2017, Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC/AHA cholesterol management guidelines: a cost-effectiveness analysis, JACC Cardiovasc Imaging, 10, 938, 10.1016/j.jcmg.2017.04.014

Cho, 2018, Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study, Eur Heart J, 39, 934, 10.1093/eurheartj/ehx774

Kavousi, 2016, Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis, JAMA, 316, 2126, 10.1001/jama.2016.17020

Lorenz, 2012, Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data, Lancet, 379, 2053, 10.1016/S0140-6736(12)60441-3

Boekholdt, 2014, Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials, J Am Coll Cardiol, 64, 485, 10.1016/j.jacc.2014.02.615

Brugts, 2009, The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials, BMJ, 338, b2376, 10.1136/bmj.b2376

Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med, 372, 2387, 10.1056/NEJMoa1410489

Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5

Fulcher, 2015, Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials, Lancet, 385, 1397, 10.1016/S0140-6736(14)61368-4

Mihaylova, 2012, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials, Lancet, 380, 581, 10.1016/S0140-6736(12)60367-5

Hegele, 2014, The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management, Lancet Diabetes Endocrinol, 2, 655, 10.1016/S2213-8587(13)70191-8

Mills, 2008, Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients, J Am Coll Cardiol, 52, 1769, 10.1016/j.jacc.2008.08.039

Pedersen, 2005, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial, JAMA, 294, 2437, 10.1001/jama.294.19.2437

Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129, S1, 10.1161/01.cir.0000437738.63853.7a

Vallejo-Vaz, 2017, Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up, Circulation, 136, 1878, 10.1161/CIRCULATIONAHA.117.027966

Tabas, 2007, Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications, Circulation, 116, 1832, 10.1161/CIRCULATIONAHA.106.676890

Boren, 2016, The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity, Curr Opin Lipidol, 27, 473, 10.1097/MOL.0000000000000330

Ference, 2018, Impact of lipids on cardiovascular health: JACC Health Promotion Series, J Am Coll Cardiol, 72, 1141, 10.1016/j.jacc.2018.06.046

Di Angelantonio, 2012, Lipid-related markers and cardiovascular disease prediction, JAMA, 307, 2499

Willer, 2013, Discovery and refinement of loci associated with lipid levels, Nat Genet, 45, 1274, 10.1038/ng.2797

Nikpay, 2015, A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease, Nat Genet, 47, 1121, 10.1038/ng.3396

Ference, 2012, Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis, J Am Coll Cardiol, 60, 2631, 10.1016/j.jacc.2012.09.017

Holmes, 2015, Mendelian randomization of blood lipids for coronary heart disease, Eur Heart J, 36, 539, 10.1093/eurheartj/eht571

Silverman, 2016, Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis, JAMA, 316, 1289, 10.1001/jama.2016.13985

Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1

Cohen, 2006, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N Engl J Med, 354, 1264, 10.1056/NEJMoa054013

Ference, 2019, Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease, JAMA, 321, 364, 10.1001/jama.2018.20045

Ference, 2015, Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study, J Am Coll Cardiol, 65, 1552, 10.1016/j.jacc.2015.02.020

Ference, 2016, Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes, N Engl J Med, 375, 2144, 10.1056/NEJMoa1604304

Sarwar, 2010, Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies, Lancet, 375, 1634, 10.1016/S0140-6736(10)60545-4

Varbo, 2013, Remnant cholesterol as a causal risk factor for ischemic heart disease, J Am Coll Cardiol, 61, 427, 10.1016/j.jacc.2012.08.1026

Lewis, 2015, Hypertriglyceridemia in the genomic era: a new paradigm, Endocr Rev, 36, 131, 10.1210/er.2014-1062

Dron, 2017, Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants, Curr Opin Lipidol, 28, 161, 10.1097/MOL.0000000000000386

Lewington, 2007, Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet, 370, 1829, 10.1016/S0140-6736(07)61778-4

Frikke-Schmidt, 2008, Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease, JAMA, 299, 2524, 10.1001/jama.299.21.2524

Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2

Lincoff, 2017, Evacetrapib and cardiovascular outcomes in high-risk vascular disease, N Engl J Med, 376, 1933, 10.1056/NEJMoa1609581

Bowman, 2017, Effects of anacetrapib in patients with atherosclerotic vascular disease, N Engl J Med, 377, 1217, 10.1056/NEJMoa1706444

Schwartz, 2012, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N Engl J Med, 367, 2089, 10.1056/NEJMoa1206797

Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579

Group, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med, 371, 203, 10.1056/NEJMoa1300955

Andrews, 2017, Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study, Cardiovasc Diagn Ther, 7, 45, 10.21037/cdt.2017.01.01

Tardif, 2014, Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial, Eur Heart J, 35, 3277, 10.1093/eurheartj/ehu171

Nordestgaard, 2016, Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology, J Lipid Res, 57, 1953, 10.1194/jlr.R071233

van der Valk, 2016, Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans, Circulation, 134, 611, 10.1161/CIRCULATIONAHA.116.020838

Nordestgaard, 2010, Lipoprotein(a) as a cardiovascular risk factor: current status, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386

Erqou, 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, 302, 412, 10.1001/jama.2009.1063

Clarke, 2009, Genetic variants associated with Lp(a) lipoprotein level and coronary disease, N Engl J Med, 361, 2518, 10.1056/NEJMoa0902604

Kamstrup, 2009, Genetically elevated lipoprotein(a) and increased risk of myocardial infarction, JAMA, 301, 2331, 10.1001/jama.2009.801

O'Donoghue, 2019, Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk, Circulation, 139, 1483, 10.1161/CIRCULATIONAHA.118.037184

Burgess, 2018, Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis, JAMA Cardiol, 3, 619, 10.1001/jamacardio.2018.1470

Parish, 2018, HPS2-THRIVE Collaborative Group. Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE Study, Circ Genom Precis Med, 11, e001696, 10.1161/CIRCGEN.117.001696

Langlois, 2018, Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM, Clin Chem, 64, 1006, 10.1373/clinchem.2018.287037

Jialal, 2017, Underestimation of low density lipoprotein-cholesterol with the Friedewald equation versus a direct homogenous low density lipoprotein-cholesterol assay, Lab Med, 48, 220, 10.1093/labmed/lmx023

Martin, 2013, Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications, J Am Coll Cardiol, 62, 732, 10.1016/j.jacc.2013.01.079

Nauck, 2002, Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation, Clin Chem, 48, 236, 10.1093/clinchem/48.2.236

Razi, 2017, LDL-cholesterol measurement in diabetic type 2 patients: a comparison between direct assay and popular equations, J Diabetes Metab Disord, 16, 43, 10.1186/s40200-017-0326-2

Robinson, 2017, Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials, J Am Coll Cardiol, 69, 471, 10.1016/j.jacc.2016.11.037

Sathiyakumar, 2018, Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy, Circulation, 137, 10, 10.1161/CIRCULATIONAHA.117.030677

Whelton, 2017, Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method, J Clin Lipidol, 11, 1065, 10.1016/j.jacl.2017.05.005

Meeusen, 2014, Validation of a proposed novel equation for estimating LDL cholesterol, Clin Chem, 60, 1519, 10.1373/clinchem.2014.227710

Langlois, 2014, Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group, Atherosclerosis, 233, 83, 10.1016/j.atherosclerosis.2013.12.016

Miida, 2012, A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects, Atherosclerosis, 225, 208, 10.1016/j.atherosclerosis.2012.08.022

Miller, 2010, Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures, Clin Chem, 56, 977, 10.1373/clinchem.2009.142810

Marcovina, 2016, Lipoprotein (a) measurements for clinical application, J Lipid Res, 57, 526, 10.1194/jlr.R061648

Marcovina, 2003, Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions, Clin Chem, 49, 1785, 10.1373/clinchem.2003.023689

Tsimikas, 2018, Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size, J Clin Lipidol, 12, 1313, 10.1016/j.jacl.2018.07.003

Mora, 2008, Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events, Circulation, 118, 993, 10.1161/CIRCULATIONAHA.108.777334

Jorgensen, 2013, Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction, Eur Heart J, 34, 1826, 10.1093/eurheartj/ehs431

Kolovou, 2011, Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement, Curr Vasc Pharmacol, 9, 258, 10.2174/157016111795495549

Mihas, 2011, Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis, Curr Vasc Pharmacol, 9, 271, 10.2174/157016111795495530

Nordestgaard, 2014, Triglycerides and cardiovascular disease, Lancet, 384, 626, 10.1016/S0140-6736(14)61177-6

Baca, 2008, Estimation of LDL-associated apolipoprotein B from measurements of triglycerides and total apolipoprotein B, Clin Chem, 54, 907, 10.1373/clinchem.2007.100941

Chapman, 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, Eur Heart J, 32, 1345, 10.1093/eurheartj/ehr112

Cartier, 2018, Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital, Clin Biochem, 52, 61, 10.1016/j.clinbiochem.2017.11.007

2014, Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease

2014, Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3), Heart, 100, ii1, 10.1136/heartjnl-2014-305693

Doran, 2014, Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III), Circulation, 130, 546, 10.1161/CIRCULATIONAHA.114.010001

Harari, 2017, Usefulness of non-high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22-year follow-up, Am J Cardiol, 119, 1193, 10.1016/j.amjcard.2017.01.008

Gu, 2015, Usefulness of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as predictors of cardiovascular disease in Chinese, Am J Cardiol, 116, 1063, 10.1016/j.amjcard.2015.06.040

van den Berg, 2016, Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B and cardiovascular risk in patients with manifest arterial disease, Am J Cardiol, 118, 804, 10.1016/j.amjcard.2016.06.048

van Deventer, 2011, Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population, Clin Chem, 57, 490, 10.1373/clinchem.2010.154773

Sniderman, 2012, Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study, Atherosclerosis, 225, 444, 10.1016/j.atherosclerosis.2012.08.039

Cook, 2018, Lipoprotein(a) and cardiovascular risk prediction among women, J Am Coll Cardiol, 72, 287, 10.1016/j.jacc.2018.04.060

Kamstrup, 2013, Extreme lipoprotein(a) levels and improved cardiovascular risk prediction, J Am Coll Cardiol, 61, 1146, 10.1016/j.jacc.2012.12.023

Willeit, 2014, Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study, J Am Coll Cardiol, 64, 851, 10.1016/j.jacc.2014.03.061

Reiner, 2011, ESC Committee for Practice Guidelines Committees (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, 32, 1769

Lloyd-Jones, 2017, 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk:, a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol, 70, 1785

Navarese, 2018, Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis, JAMA, 319, 1566, 10.1001/jama.2018.2525

Hsia, 2011, Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), J Am Coll Cardiol, 57, 1666, 10.1016/j.jacc.2010.09.082

McCormack, 2016, Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date, Int J Clin Pract, 70, 886, 10.1111/ijcp.12881

Williams, 2018, 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension, J Hypertens, 36, 1953, 10.1097/HJH.0000000000001940

Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664

Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med, 379, 2097, 10.1056/NEJMoa1801174

Charlton-Menys, 2009, Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS), Clin Chem, 55, 473, 10.1373/clinchem.2008.111401

Thompson, 2006, Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies, J Intern Med, 259, 481, 10.1111/j.1365-2796.2006.01644.x

Thanassoulis, 2014, Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials, J Am Heart Assoc, 3, e000759, 10.1161/JAHA.113.000759

Robinson, 2009, Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk, J Am Coll Cardiol, 53, 316, 10.1016/j.jacc.2008.10.024

Dalen, 2014, Diets to prevent coronary heart disease 1957-2013: what have we learned?, Am J Med, 127, 364, 10.1016/j.amjmed.2013.12.014

Eckel, 2014, 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129, S76, 10.1161/01.cir.0000437740.48606.d1

Mente, 2009, A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease, Arch Intern Med, 169, 659, 10.1001/archinternmed.2009.38

Chowdhury, 2014, Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis, Ann Intern Med, 160, 398, 10.7326/M13-1788

Mozaffarian, 2010, Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials, PLoS Med, 7, e1000252, 10.1371/journal.pmed.1000252

Forouhi, 2018, Dietary fat and cardiometabolic health: evidence, controversies, and consensus for guidance, BMJ, 361, k2139, 10.1136/bmj.k2139

Mozaffarian, 2016, Natural trans fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study, Eur Heart J, 37, 1079, 10.1093/eurheartj/ehv595

Chen, 2016, Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults, Am J Clin Nutr, 104, 1209, 10.3945/ajcn.116.134460

Moore, 1999, Effect of dietary patterns on ambulatory blood pressure : results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group, Hypertension, 34, 472, 10.1161/01.HYP.34.3.472

Sofi, 2014, Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score, Public Health Nutr, 17, 2769, 10.1017/S1368980013003169

Grosso, 2017, A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: are individual components equal?, Crit Rev Food Sci Nutr, 57, 3218, 10.1080/10408398.2015.1107021

de Lorgeril, 1999, Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study, Circulation, 99, 779, 10.1161/01.CIR.99.6.779

Estruch, 2018, Retraction and republication: primary prevention of cardiovascular disease with a Mediterranean diet, N Engl J Med, 378, 2441, 10.1056/NEJMc1806491

Mozaffarian, 2009, Health effects of trans-fatty acids: experimental and observational evidence, Eur J Clin Nutr, 63, S5, 10.1038/sj.ejcn.1602973

Clifton, 2017, A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease, Nutr Metab Cardiovasc Dis, 27, 1060, 10.1016/j.numecd.2017.10.010

Brown, 1999, Cholesterol-lowering effects of dietary fiber: a meta-analysis, Am J Clin Nutr, 69, 30, 10.1093/ajcn/69.1.30

Hollaender, 2015, Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies, Am J Clin Nutr, 102, 556, 10.3945/ajcn.115.109165

Gylling, 2014, Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease, Atherosclerosis, 232, 346, 10.1016/j.atherosclerosis.2013.11.043

Musa-Veloso, 2011, A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials, Prostaglandins Leukot Essent Fatty Acids, 85, 9, 10.1016/j.plefa.2011.02.001

Poli, 2018, Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper, Pharmacol Res, 134, 51, 10.1016/j.phrs.2018.05.015

Li, 2014, A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia, PLoS One, 9, e98611, 10.1371/journal.pone.0098611

Lu, 2008, Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction, Am J Cardiol, 101, 1689, 10.1016/j.amjcard.2008.02.056

Nordmann, 2006, Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials, Arch Intern Med, 166, 285, 10.1001/archinte.166.3.285

Zomer, 2016, Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis, Obes Rev, 17, 1001, 10.1111/obr.12433

Berger, 2015, Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis, Am J Clin Nutr, 102, 276, 10.3945/ajcn.114.100305

Griffin, 2013, Dietary cholesterol and plasma lipoprotein profiles: randomized-controlled trials, Curr Nutr Rep, 2, 274, 10.1007/s13668-013-0064-0

Shaw, 2006, Exercise for overweight or obesity, Cochrane Database Syst Rev, 4, CD003817

Droste, 2013, A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial, Nutr J, 12, 147, 10.1186/1475-2891-12-147

Rimm, 1999, Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors, BMJ, 319, 1523, 10.1136/bmj.319.7224.1523

Yu-Poth, 1999, Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis, Am J Clin Nutr, 69, 632, 10.1093/ajcn/69.4.632

Santos, 2012, Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors, Obes Rev, 13, 1048, 10.1111/j.1467-789X.2012.01021.x

Rivellese, 2003, Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects, Atherosclerosis, 167, 149, 10.1016/S0021-9150(02)00424-0

Wei, 2011, Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis, Curr Atheroscler Rep, 13, 474, 10.1007/s11883-011-0210-3

Kelishadi, 2014, Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis, Nutrition, 30, 503, 10.1016/j.nut.2013.08.014

Stanhope, 2009, Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans, J Clin Invest, 119, 1322, 10.1172/JCI37385

Gayet-Boyer, 2014, Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: results from a systematic review and meta-regression of randomised clinical trials, Br J Nutr, 112, 1914, 10.1017/S0007114514002578

Kelley, 2009, Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials, Prev Med, 48, 9, 10.1016/j.ypmed.2008.10.010

Kastorini, 2011, The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals, J Am Coll Cardiol, 57, 1299, 10.1016/j.jacc.2010.09.073

Maeda, 2003, The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis, Prev Med, 37, 283, 10.1016/S0091-7435(03)00110-5

Mensink, 2003, Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials, Am J Clin Nutr, 77, 1146, 10.1093/ajcn/77.5.1146

Micha, 2014, Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys, BMJ, 348, g2272, 10.1136/bmj.g2272

Schwingshackl, 2018, Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis, J Lipid Res, 59, 1771, 10.1194/jlr.P085522

Dattilo, 1992, Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis, Am J Clin Nutr, 56, 320, 10.1093/ajcn/56.2.320

Huffman, 2012, Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in studies of a targeted risk reduction intervention through defined exercise I, Am Heart J, 164, 117, 10.1016/j.ahj.2012.04.014

Kraus, 2002, Effects of the amount and intensity of exercise on plasma lipoproteins, N Engl J Med, 347, 1483, 10.1056/NEJMoa020194

Brien, 2011, Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies, BMJ, 342, d636, 10.1136/bmj.d636

De Natale, 2009, Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients, Diabetes Care, 32, 2168, 10.2337/dc09-0266

Liu, 2001, Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women, Am J Clin Nutr, 73, 560, 10.1093/ajcn/73.3.560

Stanhope, 2015, A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults, Am J Clin Nutr, 101, 1144, 10.3945/ajcn.114.100461

Taskinen, 2017, Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity, J Intern Med, 282, 187, 10.1111/joim.12632

Wing, 2013, Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes, N Engl J Med, 369, 145, 10.1056/NEJMoa1212914

Batsis, 2017, Weight loss interventions in older adults with obesity: a systematic review of randomized controlled trials since 2005, J Am Geriatr Soc, 65, 257, 10.1111/jgs.14514

Harris, 2009, Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention, Circulation, 119, 902, 10.1161/CIRCULATIONAHA.108.191627

Mozaffarian, 2013, Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study, Ann Intern Med, 158, 515, 10.7326/0003-4819-158-7-201304020-00003

Riccardi, 2016, How well can we control dyslipidemias through lifestyle modifications?, Curr Cardiol Rep, 18, 66, 10.1007/s11886-016-0744-7

Seidelmann, 2018, Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis, Lancet Public Health, 3, e419, 10.1016/S2468-2667(18)30135-X

Dehghan, 2018, Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study, Lancet, 392, 2288, 10.1016/S0140-6736(18)31812-9

Poli, 2008, Non-pharmacological control of plasma cholesterol levels, Nutr Metab Cardiovasc Dis, 18, S1, 10.1016/j.numecd.2007.10.004

2018, Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet, 392, 1015, 10.1016/S0140-6736(18)31310-2

Wood, 2018, Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies, Lancet, 391, 1513, 10.1016/S0140-6736(18)30134-X

De Backer, 2017, Food supplements with red yeast rice: more regulations are needed, Eur J Prev Cardiol, 24, 1429, 10.1177/2047487317716500

Hartley, 2016, Dietary fibre for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev, 1, CD011472

Pirro, 2017, Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA), Nutr Metab Cardiovasc Dis, 27, 2, 10.1016/j.numecd.2016.11.122

Dewell, 2006, Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations, J Clin Endocrinol Metab, 91, 772, 10.1210/jc.2004-2350

Mas, 1999, Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors, Clin Pharmacol Ther, 65, 439, 10.1016/S0009-9236(99)70139-6

Reiner, 2005, Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients, Clin Drug Investig, 25, 701, 10.2165/00044011-200525110-00003

Lan, 2015, Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension, J Ethnopharmacol, 161, 69, 10.1016/j.jep.2014.09.049

Sacks, 2017, Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association, Circulation, 136, e1, 10.1161/CIR.0000000000000510

Jacobson, 2012, Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review, J Clin Lipidol, 6, 5, 10.1016/j.jacl.2011.10.018

Bhatt, 2019, Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia, N Engl J Med, 380, 11, 10.1056/NEJMoa1812792

Chasman, 2012, Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, Circ Cardiovasc Genet, 5, 257, 10.1161/CIRCGENETICS.111.961144

Reiner, 2014, Resistance and intolerance to statins, Nutr Metab Cardiovasc Dis, 24, 1057, 10.1016/j.numecd.2014.05.009

Moriarty, 2015, Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial, J Clin Lipidol, 9, 758, 10.1016/j.jacl.2015.08.006

Stroes, 2014, Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab, J Am Coll Cardiol, 63, 2541, 10.1016/j.jacc.2014.03.019

Reiner, 2013, Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update, Nutr Metab Cardiovasc Dis, 23, 799, 10.1016/j.numecd.2013.05.002

Sharma, 2014, Baseline very low-density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia, J Cardiovasc Transl Res, 7, 465, 10.1007/s12265-014-9559-3

Barter, 2010, Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database, J Lipid Res, 51, 1546, 10.1194/jlr.P002816

Tsimikas, 2004, High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial, Circulation, 110, 1406, 10.1161/01.CIR.0000141728.23033.B5

Khera, 2014, Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), Circulation, 129, 635, 10.1161/CIRCULATIONAHA.113.004406

Davignon, 2004, Beneficial cardiovascular pleiotropic effects of statins, Circulation, 109, III39, 10.1161/01.CIR.0000131517.20177.5a

Oesterle, 2017, Pleiotropic effects of statins on the cardiovascular system, Circ Res, 120, 229, 10.1161/CIRCRESAHA.116.308537

Pedersen, 2010, Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering, Am J Cardiovasc Drugs, 10, 10, 10.2165/1158822-S0-000000000-00000

Genser, 2006, Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis, Clin Res Cardiol, 95, 393, 10.1007/s00392-006-0403-x

Gould, 1995, Cholesterol reduction yields clinical benefit. A new look at old data, Circulation, 91, 2274, 10.1161/01.CIR.91.8.2274

Gould, 1998, Cholesterol reduction yields clinical benefit: impact of statin trials, Circulation, 97, 946, 10.1161/01.CIR.97.10.946

LaRosa, 1999, Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials, JAMA, 282, 2340, 10.1001/jama.282.24.2340

Mills, 2011, Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials, QJM, 104, 109, 10.1093/qjmed/hcq165

Ray, 2010, Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants, Arch Intern Med, 170, 1024, 10.1001/archinternmed.2010.182

Taylor, 2013, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev, 1, CD004816

Herrington, 2016, Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials, Lancet Diabetes Endocrinol, 4, 829, 10.1016/S2213-8587(16)30156-5

Naci, 2013, Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials, Eur J Prev Cardiol, 20, 641, 10.1177/2047487313480435

Ford, 2016, Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study, Circulation, 133, 1073, 10.1161/CIRCULATIONAHA.115.019014

2019, Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials, Lancet, 393, 407, 10.1016/S0140-6736(18)31942-1

Rogers, 2014, Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure), JACC Heart Fail, 2, 289, 10.1016/j.jchf.2013.12.007

Tavazzi, 2008, Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1231, 10.1016/S0140-6736(08)61240-4

Wanner, 2005, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis, N Engl J Med, 353, 238, 10.1056/NEJMoa043545

Fellström, 2009, Rosuvastatin and cardiovascular events in patients undergoing hemodialysis, N Engl J Med, 360, 1395, 10.1056/NEJMoa0810177

Baigent, 2011, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet, 377, 2181, 10.1016/S0140-6736(11)60739-3

Emberson, 2012, Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy, PLoS One, 7, e29849, 10.1371/journal.pone.0029849

McGuinness, 2014, Statins for the treatment of dementia, Cochrane Database Syst Rev, 7, CD007514

Eslami, 2013, Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, Cochrane Database Syst Rev, 12, CD008623

Rahimi, 2012, Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials, PLoS Med, 9, e1001310, 10.1371/journal.pmed.1001310

Rahimi, 2011, Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials, BMJ, 342, d1250, 10.1136/bmj.d1250

Zheng, 2016, Perioperative rosuvastatin in cardiac surgery, N Engl J Med, 374, 1744, 10.1056/NEJMoa1507750

Raval, 2011, Statins for women with polycystic ovary syndrome not actively trying to conceive, Cochrane Database Syst Rev, 10, CD008565

McGuinness, 2016, Statins for the prevention of dementia, Cochrane Database Syst Rev, 1, CD003160

Giugliano, 2017, Cognitive function in a randomized trial of evolocumab, N Engl J Med, 377, 633, 10.1056/NEJMoa1701131

Mach, 2018, Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract, Eur Heart J, 39, 2526, 10.1093/eurheartj/ehy182

Collins, 2016, Interpretation of the evidence for the efficacy and safety of statin therapy, Lancet, 388, 2532, 10.1016/S0140-6736(16)31357-5

Stroes, 2015, Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management, Eur Heart J, 36, 1012, 10.1093/eurheartj/ehv043

Law, 2006, Statin safety: a systematic review, Am J Cardiol, 97, 52C, 10.1016/j.amjcard.2005.12.010

Bruckert, 2005, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study, Cardiovasc Drugs Ther, 19, 403, 10.1007/s10557-005-5686-z

Davidson, 2006, Statin safety: an appraisal from the adverse event reporting system, Am J Cardiol, 97, 32C, 10.1016/j.amjcard.2005.12.008

Gupta, 2017, ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase, Lancet, 389, 2473, 10.1016/S0140-6736(17)31075-9

Finegold, 2014, What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice, Eur J Prev Cardiol, 21, 464, 10.1177/2047487314525531

Naci, 2013, Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials, Circ Cardiovasc Qual Outcomes, 6, 390, 10.1161/CIRCOUTCOMES.111.000071

Moriarty, 2014, Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial, J Clin Lipidol, 8, 554, 10.1016/j.jacl.2014.09.007

Keating, 2013, Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy, Ann Pharmacother, 47, 398, 10.1345/aph.1R509

Marcum, 2012, FDA drug safety communications: a narrative review and clinical considerations for older adults, Am J Geriatr Pharmacother, 10, 264, 10.1016/j.amjopharm.2012.05.002

Chalasani, 2004, Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity, Gastroenterology, 126, 1287, 10.1053/j.gastro.2004.02.015

Dongiovanni, 2015, Statin use and non-alcoholic steatohepatitis in at risk individuals, J Hepatol, 63, 705, 10.1016/j.jhep.2015.05.006

Vuppalanchi, 2005, Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes, Am J Med Sci, 329, 62, 10.1097/00000441-200502000-00002

Sattar, 2010, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet, 375, 735, 10.1016/S0140-6736(09)61965-6

Preiss, 2011, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis, JAMA, 305, 2556, 10.1001/jama.2011.860

Waters, 2013, Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes, J Am Coll Cardiol, 61, 148, 10.1016/j.jacc.2012.09.042

Swerdlow, 2015, HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials, Lancet, 385, 351, 10.1016/S0140-6736(14)61183-1

McKinney, 2012, Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials, Stroke, 43, 2149, 10.1161/STROKEAHA.112.655894

Hackam, 2011, Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis, Circulation, 124, 2233, 10.1161/CIRCULATIONAHA.111.055269

Palmer, 2014, HMG CoA reductase inhibitors (statins) for kidney transplant recipients, Cochrane Database Syst Rev, 1, CD005019

Agarwal, 2006, Effects of statins on renal function, Am J Cardiol, 97, 748, 10.1016/j.amjcard.2005.09.110

Sidaway, 2004, Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells, J Am Soc Nephrol, 15, 2258, 10.1097/01.ASN.0000138236.82706.EE

Davidson, 2004, Rosuvastatin safety: lessons from the FDA review and post-approval surveillance, Expert Opin Drug Saf, 3, 547, 10.1517/14740338.3.6.547

Egan, 2011, Weighing the benefits of high-dose simvastatin against the risk of myopathy, N Engl J Med, 365, 285, 10.1056/NEJMp1106689

Wiklund, 2013, Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy, Curr Cardiol Rep, 15, 397, 10.1007/s11886-013-0397-8

Franssen, 2009, Combination statin-fibrate therapy: safety aspects, Diabetes Obes Metab, 11, 89, 10.1111/j.1463-1326.2008.00917.x

Holoshitz, 2008, Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use, Am J Cardiol, 101, 95, 10.1016/j.amjcard.2007.07.057

Phan, 2012, Ezetimibe therapy: mechanism of action and clinical update, Vasc Health Risk Manag, 8, 415

Pandor, 2009, Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials, J Intern Med, 265, 568, 10.1111/j.1365-2796.2008.02062.x

Morrone, 2012, Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials, Atherosclerosis, 223, 251, 10.1016/j.atherosclerosis.2012.02.016

Jones, 2013, Role of colesevelam in combination lipid-lowering therapy, Am J Cardiovasc Drugs, 13, 315, 10.1007/s40256-013-0037-0

Nissen, 2016, Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial, JAMA, 315, 1580, 10.1001/jama.2016.3608

Rossebø, 2008, Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis, N Engl J Med, 359, 1343, 10.1056/NEJMoa0804602

2010, Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease, Am Heart J, 160, 785, 10.1016/j.ahj.2010.08.012

Ference, 2018, Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration, Eur Heart J, 39, 2540, 10.1093/eurheartj/ehx450

Stitziel, 2014, Inactivating mutations in NPC1L1 and protection from coronary heart disease, N Engl J Med, 371, 2072, 10.1056/NEJMoa1405386

Pirillo, 2016, Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases, Curr Med Chem, 23, 983, 10.2174/0929867323666160229114111

Tsujita, 2015, Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial, J Am Coll Cardiol, 66, 495, 10.1016/j.jacc.2015.05.065

Khan, 2018, A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes, Eur J Prev Cardiol, 25, 844, 10.1177/2047487318766612

Koskinas, 2018, Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials, Eur Heart J, 39, 1172, 10.1093/eurheartj/ehx566

Mazidi, 2017, The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: a systematic review and meta-analysis of randomized controlled trials, Int J Cardiol, 227, 850, 10.1016/j.ijcard.2016.10.011

Ooi, 2014, Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review, Diabet Med, 31, 2, 10.1111/dme.12295

1983, Pre-entry characteristics of participants in the Lipid Research Clinics' Coronary Primary Prevention Trial, J Chronic Dis, 36, 467, 10.1016/0021-9681(83)90138-8

1984, The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025

1992, The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators, Arch Intern Med, 152, 1399, 10.1001/archinte.1992.00400190041009

He, 2014, Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin, Diabetes Res Clin Pract, 104, 401, 10.1016/j.diabres.2013.12.033

Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat Genet, 34, 154, 10.1038/ng1161

Norata, 2014, Targeting PCSK9 for hypercholesterolemia, Annu Rev Pharmacol Toxicol, 54, 273, 10.1146/annurev-pharmtox-011613-140025

Nozue, 2017, Lipid lowering therapy and circulating PCSK9 concentration, J Atheroscler Thromb, 24, 895, 10.5551/jat.RV17012

Cho, 2016, Clinical profile of statin intolerance in the phase 3 GAUSS-2 Study, Cardiovasc Drugs Ther, 30, 297, 10.1007/s10557-016-6655-4

Schmidt, 2017, PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease, Cochrane Database Syst Rev, 4, CD011748

Thedrez, 2018, Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of evolocumab, Arterioscler Thromb Vasc Biol, 38, 592, 10.1161/ATVBAHA.117.310217

Robinson, 2015, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N Engl J Med, 372, 1489, 10.1056/NEJMoa1501031

Stein, 2017, Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?, Expert Rev Cardiovasc Ther, 15, 491, 10.1080/14779072.2017.1348231

Gaudet, 2014, Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials), Am J Cardiol, 114, 711, 10.1016/j.amjcard.2014.05.060

Raal, 2014, Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials, J Am Coll Cardiol, 63, 1278, 10.1016/j.jacc.2014.01.006

Sabatine, 2015, Efficacy and safety of evolocumab in reducing lipids and cardiovascular events, N Engl J Med, 372, 1500, 10.1056/NEJMoa1500858

Navarese, 2016, Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review, Ann Intern Med, 164, 600, 10.7326/M15-2994

Cicero, 2014, Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data, Expert Opin Drug Saf, 13, 1023, 10.1517/14740338.2014.932348

Lipinski, 2016, The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis, Eur Heart J, 37, 536, 10.1093/eurheartj/ehv563

Schmidt, 2017, PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study, Lancet Diabetes Endocrinol, 5, 97, 10.1016/S2213-8587(16)30396-5

Cao, 2018, Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: a systematic review and meta-analysis, Diabetes Obes Metab, 20, 1391, 10.1111/dom.13235

de Carvalho, 2018, Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years, Diabetes Care, 41, 364, 10.2337/dc17-1464

Sabatine, 2017, Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial, Lancet Diabetes Endocrinol, 5, 941, 10.1016/S2213-8587(17)30313-3

Zhang, 2016, Comparative efficacy and safety of everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stents: a systematic review and meta-analysis, Ann Intern Med, 164, 752, 10.7326/M16-0006

Giugliano, 2018, Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), Circulation, 137, 1571, 10.1161/CIRCULATIONAHA.117.030950

Ridker, 2017, Lipid-reduction variability and antidrug-antibody formation with bococizumab, N Engl J Med, 376, 1517, 10.1056/NEJMoa1614062

Cuchel, 2013, Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study, Lancet, 381, 40, 10.1016/S0140-6736(12)61731-0

Cuchel, 2007, Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia, N Engl J Med, 356, 148, 10.1056/NEJMoa061189

Agarwala, 2015, The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations, Curr Atheroscler Rep, 17, 467, 10.1007/s11883-014-0467-4

Li, 2014, Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials, Am J Cardiovasc Drugs, 14, 367, 10.1007/s40256-014-0077-0

Chapman, 2010, Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk, Pharmacol Ther, 126, 314, 10.1016/j.pharmthera.2010.01.008

Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, 362, 1563, 10.1056/NEJMoa1001282

Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2

Frick, 1987, Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease, N Engl J Med, 317, 1237, 10.1056/NEJM198711123172001

Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604

1992, Circulation, 839

Meade, 2002, Bezafibrate in men with lower extremity arterial disease: randomised controlled trial, BMJ, 325, 1139, 10.1136/bmj.325.7373.1139

Ip, 2015, Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials, Int J Cardiol, 191, 138, 10.1016/j.ijcard.2015.04.228

Keene, 2014, Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients, BMJ, 349, g4379, 10.1136/bmj.g4379

Bruckert, 2011, Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis, J Cardiovasc Pharmacol, 57, 267, 10.1097/FJC.0b013e318202709f

Jun, 2012, Effects of fibrates in kidney disease: a systematic review and meta-analysis, J Am Coll Cardiol, 60, 2061, 10.1016/j.jacc.2012.07.049

Lee, 2011, Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis, Atherosclerosis, 217, 492, 10.1016/j.atherosclerosis.2011.04.020

Fruchart, 2017, Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia, Cardiovasc Diabetol, 16, 124, 10.1186/s12933-017-0602-y

Pradhan, 2018, Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study, Am Heart J, 206, 80, 10.1016/j.ahj.2018.09.011

Davidson, 2007, Safety considerations with fibrate therapy, Am J Cardiol, 99, 3C, 10.1016/j.amjcard.2006.11.016

Graham, 2004, Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs, JAMA, 292, 2585, 10.1001/jama.292.21.2585

Preiss, 2012, Lipid-modifying therapies and risk of pancreatitis: a meta-analysis, JAMA, 308, 804, 10.1001/jama.2012.8439

Taskinen, 2009, Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate, Arterioscler Thromb Vasc Biol, 29, 950, 10.1161/ATVBAHA.108.178228

Balk, 2006, Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review, Atherosclerosis, 189, 19, 10.1016/j.atherosclerosis.2006.02.012

Ballantyne, 2012, Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study), Am J Cardiol, 110, 984, 10.1016/j.amjcard.2012.05.031

Bays, 2011, Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial), Am J Cardiol, 108, 682, 10.1016/j.amjcard.2011.04.015

Kastelein, 2014, Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial, J Clin Lipidol, 8, 94, 10.1016/j.jacl.2013.10.003

Stroes, 2018, Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial, J Clin Lipidol, 12, 321, 10.1016/j.jacl.2017.10.012

Abdelhamid, 2018, Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease, Cochrane Database Syst Rev, 7, CD003177

Bowman, 2018, Effects of n-3 fatty acid supplements in diabetes mellitus, N Engl J Med, 379, 1540, 10.1056/NEJMoa1804989

Hooper, 2006, Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review, BMJ, 332, 752, 10.1136/bmj.38755.366331.2F

Marchioli, 2002, Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione, Circulation, 105, 1897, 10.1161/01.CIR.0000014682.14181.F2

Nicholls, 2018, Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial, Clin Cardiol, 41, 1281, 10.1002/clc.23055

Manson, 2019, Marine n-3 fatty acids and prevention of cardiovascular disease and cancer, N Engl J Med, 380, 23, 10.1056/NEJMoa1811403

Brasky, 2013, Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial, J Natl Cancer Inst, 105, 1132, 10.1093/jnci/djt174

Kamanna, 2008, Mechanism of action of niacin, Am J Cardiol, 101, 20B, 10.1016/j.amjcard.2008.02.029

Barter, 2007, Effects of torcetrapib in patients at high risk for coronary events, N Engl J Med, 357, 2109, 10.1056/NEJMoa0706628

Ference, 2017, Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk, JAMA, 318, 947, 10.1001/jama.2017.11467

Fitzgerald, 2017, A highly durable RNAi therapeutic inhibitor of PCSK9, N Engl J Med, 376, 41, 10.1056/NEJMoa1609243

Ray, 2017, Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol, N Engl J Med, 376, 1430, 10.1056/NEJMoa1615758

Saeed, 2018, Bempedoic acid (ETC-1002): a current review, Cardiol Clin, 36, 257, 10.1016/j.ccl.2017.12.007

Ballantyne, 2018, Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study, Atherosclerosis, 277, 195, 10.1016/j.atherosclerosis.2018.06.002

Ray, 2019, Safety and efficacy of bempedoic acid to reduce LDL cholesterol, N Engl J Med, 380, 1022, 10.1056/NEJMoa1803917

Stitziel, 2017, ANGPTL3 deficiency and protection against coronary artery disease, J Am Coll Cardiol, 69, 2054, 10.1016/j.jacc.2017.02.030

Gaudet, 2017, ANGPTL3 inhibition in homozygous familial hypercholesterolemia, N Engl J Med, 377, 296, 10.1056/NEJMc1705994

Graham, 2017, Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides, N Engl J Med, 377, 222, 10.1056/NEJMoa1701329

Graham, 2013, Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans, Circ Res, 112, 1479, 10.1161/CIRCRESAHA.111.300367

Gouni-Berthold, 2017, Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial, Atherosclerosis Supp, 28, e1, 10.1016/j.atherosclerosissup.2017.08.003

Gaudet, 2017, The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS), Atherosclerosis, 263, e10, 10.1016/j.atherosclerosis.2017.06.059

Rocha, 2017, ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen, Curr Atheroscler Rep, 19, 62, 10.1007/s11883-017-0697-3

Didichenko, 2016, Enhanced HDL functionality in small HDL species produced upon remodeling of HDL by reconstituted HDL, CSL112: effects on cholesterol efflux, anti-inflammatory and antioxidative activity, Circ Res, 119, 751, 10.1161/CIRCRESAHA.116.308685

Digenio, 2016, Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes, Diabetes Care, 39, 1408, 10.2337/dc16-0126

Viney, 2016, Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials, Lancet, 388, 2239, 10.1016/S0140-6736(16)31009-1

Schreml, 2018, Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance, Curr Med Chem, 25, 1538, 10.2174/0929867324666170616111647

Maki, 2016, Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia, J Clin Lipidol, 10, 905, 10.1016/j.jacl.2016.03.008

Vallejo-Vaz, 2018, Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial, Circulation, 138, 770, 10.1161/CIRCULATIONAHA.117.032318

Catapano, 2014, Combination therapy in dyslipidemia: where are we now?, Atherosclerosis, 237, 319, 10.1016/j.atherosclerosis.2014.09.026

Willer, 2013, Discovery and refinement of loci associated with lipid levels, Nat Genet, 45, 1274, 10.1038/ng.2797

Brahm, 2016, Combined hyperlipidemia: familial but not (usually) monogenic, Curr Opin Lipidol, 27, 131, 10.1097/MOL.0000000000000270

Ripatti, 2016, The contribution of GWAS loci in familial dyslipidemias, PLoS Genet, 12, e1006078, 10.1371/journal.pgen.1006078

Veerkamp, 2002, Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study, Arterioscler Thromb Vasc Biol, 22, 274, 10.1161/hq0202.104059

Akioyamen, 2017, Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis, BMJ Open, 7, e016461, 10.1136/bmjopen-2017-016461

de Ferranti, 2016, Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES), Circulation, 133, 1067, 10.1161/CIRCULATIONAHA.115.018791

Nordestgaard, 2013, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society, Eur Heart J, 34, 3478, 10.1093/eurheartj/eht273

1991, Scientific Steering Committee on behalf of the Simon Broome Register Group, BMJ, 303, 893, 10.1136/bmj.303.6807.893

1999

Landmesser, 2017, European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk, Eur Heart J, 38, 2245

Ridker, 2017, Cardiovascular efficacy and safety of bococizumab in high-risk patients, N Engl J Med, 376, 1527, 10.1056/NEJMoa1701488

Cuchel, 2014, Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society, Eur Heart J, 35, 2146, 10.1093/eurheartj/ehu274

Wiegman, 2015, Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment, Eur Heart J, 36, 2425, 10.1093/eurheartj/ehv157

Braamskamp, 2017, Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label), Circulation, 136, 359, 10.1161/CIRCULATIONAHA.116.025158

Vuorio, 2017, Statins for children with familial hypercholesterolemia, Cochrane Database Syst Rev, 7, CD006401

Reiner, 2018, Treatment of children with homozygous familial hypercholesterolaemia, Eur J Prev Cardiol, 25, 1095, 10.1177/2047487318781360

Koopal, 2017, Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder, Curr Opin Endocrinol Diabetes Obes, 24, 133, 10.1097/MED.0000000000000316

Mahley, 2009, Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS, J Lipid Res, 50, S183, 10.1194/jlr.R800069-JLR200

Marais, 2015, Dysbetalipoproteinemia: an extreme disorder of remnant metabolism, Curr Opin Lipidol, 26, 292, 10.1097/MOL.0000000000000192

Sniderman, 2010, Diagnosis and treatment of apolipoprotein B dyslipoproteinemias, Nat Rev Endocrinol, 6, 335, 10.1038/nrendo.2010.50

Brahm, 2015, Chylomicronaemia--current diagnosis and future therapies, Nat Rev Endocrinol, 11, 352, 10.1038/nrendo.2015.26

Bauer, 2016, Therapeutic targets of triglyceride metabolism as informed by human genetics, Trends Mol Med, 22, 328, 10.1016/j.molmed.2016.02.005

Gaudet, 2013, Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial, Gene Ther, 20, 361, 10.1038/gt.2012.43

Huff, 2013, Apolipoprotein C-III: going back to the future for a lipid drug target, Circ Res, 112, 1405, 10.1161/CIRCRESAHA.113.301464

Moulin, 2018, Atherosclerosis, 275, 265, 10.1016/j.atherosclerosis.2018.06.814

Meyers, 2015, Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome, Lipids Health Dis, 14, 8, 10.1186/s12944-015-0006-5

Lindkvist, 2012, A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose, Pancreatology, 12, 317, 10.1016/j.pan.2012.05.002

Ewald, 2009, Severe hypertriglyceridemia and pancreatitis: presentation and management, Curr Opin Lipidol, 20, 497, 10.1097/MOL.0b013e3283319a1d

Chora, 2017, Lysosomal acid lipase deficiency: a hidden disease among cohorts of familial hypercholesterolemia?, J Clin Lipidol, 11, 477, 10.1016/j.jacl.2016.11.002

Burton, 2015, A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency, N Engl J Med, 373, 1010, 10.1056/NEJMoa1501365

Hague, 2003, Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study, Am Heart J, 145, 643, 10.1067/mhj.2003.1

Miettinen, 1997, Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S), Circulation, 96, 4211, 10.1161/01.CIR.96.12.4211

d'Emden, 2014, Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, Diabetologia, 57, 2296, 10.1007/s00125-014-3344-3

Spitzer, 2002, Myocardial infarction and third generation oral contraceptives: aggregation of recent studies, Hum Reprod, 17, 2307, 10.1093/humrep/17.9.2307

Shufelt, 2009, Contraceptive hormone use and cardiovascular disease, J Am Coll Cardiol, 53, 221, 10.1016/j.jacc.2008.09.042

Manson, 2003, Estrogen plus progestin and the risk of coronary heart disease, N Engl J Med, 349, 523, 10.1056/NEJMoa030808

Rosengren, 2012, Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth?, Eur Heart J, 33, 562, 10.1093/eurheartj/ehr364

1998, Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention, Eur Heart J, 19, 1434, 10.1053/euhj.1998.1243

Koopman, 2013, Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010, Eur Heart J, 34, 3198, 10.1093/eurheartj/eht368

Salami, 2017, National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey, JAMA Cardiol, 2, 56, 10.1001/jamacardio.2016.4700

Strandberg, 2014, Evaluation and treatment of older patients with hypercholesterolemia: a clinical review, JAMA, 312, 1136, 10.1001/jama.2014.10924

Mangin, 2007, Preventive health care in elderly people needs rethinking, BMJ, 335, 285, 10.1136/bmj.39241.630741.BE1

Zimmet, 2017, Diabetes and its drivers: the largest epidemic in human history?, Clin Diabetes Endocrinol, 3, 1, 10.1186/s40842-016-0039-3

Rawshani, 2017, Mortality and cardiovascular disease in type 1 and type 2 diabetes, N Engl J Med, 376, 1407, 10.1056/NEJMoa1608664

Olesen, 2017, Patients with diabetes without significant angiographic coronary artery disease have the same risk of myocardial infarction as patients without diabetes in a real-world population receiving appropriate prophylactic treatment, Diabetes Care, 40, 1103, 10.2337/dc16-2388

Sarwar, 2010, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies, Lancet, 375, 2215, 10.1016/S0140-6736(10)60484-9

Gregg, 2014, Changes in diabetes-related complications in the United States, 1990-2010, N Engl J Med, 370, 1514, 10.1056/NEJMoa1310799

Sattar, 2013, Revisiting the links between glycaemia, diabetes and cardiovascular disease, Diabetologia, 56, 686, 10.1007/s00125-012-2817-5

Brownrigg, 2016, Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study, Lancet Diabetes Endocrinol, 4, 588, 10.1016/S2213-8587(16)30057-2

Despres, 2012, Body fat distribution and risk of cardiovascular disease: an update, Circulation, 126, 1301, 10.1161/CIRCULATIONAHA.111.067264

Targher, 2017, Non-alcoholic fatty liver disease as driving force in coronary heart disease?, Gut, 66, 213, 10.1136/gutjnl-2016-312891

Targher, 2018, Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus, Nat Rev Endocrinol, 14, 99, 10.1038/nrendo.2017.173

Donahoe, 2007, Diabetes and mortality following acute coronary syndromes, JAMA, 298, 765, 10.1001/jama.298.7.765

Levesque, 2017, Relation between a simple lifestyle risk score and established biological risk factors for cardiovascular disease, Am J Cardiol, 120, 1939, 10.1016/j.amjcard.2017.08.008

Taskinen, 2015, New insights into the pathophysiology of dyslipidemia in type 2 diabetes, Atherosclerosis, 239, 483, 10.1016/j.atherosclerosis.2015.01.039

Taskinen, 2016, Why is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?, Curr Atheroscler Rep, 18, 59, 10.1007/s11883-016-0614-1

Boren, 2015, Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: multicenter tracer kinetic study, Arterioscler Thromb Vasc Biol, 35, 2218, 10.1161/ATVBAHA.115.305614

Gordts, 2016, ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors, J Clin Invest, 126, 2855, 10.1172/JCI86610

Mark, 2015, Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: a nationwide survey of 2674 individuals in Hungary, Atherosclerosis, 241, 62, 10.1016/j.atherosclerosis.2015.04.810

Scott, 2009, Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, Diabetes Care, 32, 493, 10.2337/dc08-1543

Annuzzi, 2008, Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance, Nutr Metab Cardiovasc Dis, 18, 531, 10.1016/j.numecd.2007.12.003

Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet, 371, 117, 10.1016/S0140-6736(08)60104-X

2018, Cardiovascular disease and risk management: standards of medical care in diabetes-2018, Diabetes Care, 41, S86, 10.2337/dc18-S009

Ray, 2019, Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial, Lancet Diabetes Endocrinol, 10.1016/S2213-8587(19)30158-5

Elam, 2017, Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes, JAMA Cardiol, 2, 370, 10.1001/jamacardio.2016.4828

Saha, 2010, Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials, Int J Cardiol, 141, 157, 10.1016/j.ijcard.2008.11.211

Araki, 2018, Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial, Diabetes Care, 41, 538, 10.2337/dc17-1589

Arca, 2018, Hypertriglyceridemia and omega-3 fatty acids: their often overlooked role in cardiovascular disease prevention, Nutr Metab Cardiovasc Dis, 28, 197, 10.1016/j.numecd.2017.11.001

Bhatt, 2017, Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial, Clin Cardiol, 40, 138, 10.1002/clc.22692

Bowman, 2018, Effects of aspirin for primary prevention in persons with diabetes mellitus, N Engl J Med, 379, 1529, 10.1056/NEJMoa1804988

Laing, 2003, Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes, Diabetologia, 46, 760, 10.1007/s00125-003-1116-6

Chillaron, 2014, Type 1 diabetes, metabolic syndrome and cardiovascular risk, Metabolism, 63, 181, 10.1016/j.metabol.2013.10.002

Annuzzi, 2001, Effect of acute exogenous hyperinsulinaemia on very low density lipoprotein subfraction composition in normal subjects, Eur J Clin Invest, 31, 118, 10.1046/j.1365-2362.2001.00779.x

Cannon, 2006, Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy, J Am Coll Cardiol, 48, 438, 10.1016/j.jacc.2006.04.070

Mills, 2011, Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients, Eur Heart J, 32, 1409, 10.1093/eurheartj/ehr035

Nicholls, 2008, Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials, J Am Coll Cardiol, 52, 255, 10.1016/j.jacc.2008.03.051

Karalis, 2016, The risks of statin use in pregnancy: a systematic review, J Clin Lipidol, 10, 1081, 10.1016/j.jacl.2016.07.002

Gencer, 2017, Eligibility for PCSK9 inhibitors according to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines after acute coronary syndromes, J Am Heart Assoc, 6, e006537, 10.1161/JAHA.117.006537

Kureshi, 2016, Association between cardiac rehabilitation participation and health status outcomes after acute myocardial infarction, JAMA Cardiol, 1, 980, 10.1001/jamacardio.2016.3458

Szummer, 2017, Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014, Eur Heart J, 38, 3056, 10.1093/eurheartj/ehx515

Gitt, 2017, Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II, Atherosclerosis, 266, 158, 10.1016/j.atherosclerosis.2017.08.013

de Lemos, 2004, Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial, JAMA, 292, 1307, 10.1001/jama.292.11.1307

Navarese, 2014, Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention, Am J Cardiol, 113, 1753, 10.1016/j.amjcard.2014.02.034

Ray, 2005, Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial, J Am Coll Cardiol, 46, 1405, 10.1016/j.jacc.2005.03.077

Schwartz, 2017, Early, intensive statin treatment reduces ‘hard’ cardiovascular outcomes after acute coronary syndrome, Eur J Prev Cardiol, 24, 1294, 10.1177/2047487317708677

Schwartz, 2001, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial, JAMA, 285, 1711, 10.1001/jama.285.13.1711

Berwanger, 2018, Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial, JAMA, 319, 1331, 10.1001/jama.2018.2444

Kato, 2017, Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), J Am Heart Assoc, 6, e006901, 10.1161/JAHA.117.006901

Murphy, 2016, Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial, J Am Coll Cardiol, 67, 353, 10.1016/j.jacc.2015.10.077

Bohula, 2017, Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), Circulation, 136, 2440, 10.1161/CIRCULATIONAHA.117.029095

Pokharel, 2017, Impact of ezetimibe on the rate of cardiovascular-related hospitalizations and associated costs among patients with a recent acute coronary syndrome: results from the IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), Circ Cardiovasc Qual Outcomes, 10, e003201, 10.1161/CIRCOUTCOMES.116.003201

Bohula, 2017, Atherothrombotic risk stratification and ezetimibe for secondary prevention, J Am Coll Cardiol, 69, 911, 10.1016/j.jacc.2016.11.070

Hagiwara, 2017, Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial, Eur Heart J, 38, 2264, 10.1093/eurheartj/ehx162

Sabatine, 2018, Clinical benefit of evolocumab by severity and extent of coronary artery disease, Circulation, 138, 756, 10.1161/CIRCULATIONAHA.118.034309

Giugliano, 2017, Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial, Lancet, 390, 1962, 10.1016/S0140-6736(17)32290-0

Koskinas, 2018, Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial, Clin Cardiol, 41, 1513, 10.1002/clc.23112

Aung, 2018, Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals, JAMA Cardiol, 3, 225, 10.1001/jamacardio.2017.5205

Patti, 2011, Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies, Circulation, 123, 1622, 10.1161/CIRCULATIONAHA.110.002451

Kim, 2010, Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial, JACC Cardiovasc Interv, 3, 332, 10.1016/j.jcin.2009.11.021

Briguori, 2009, Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction, J Am Coll Cardiol, 54, 2157, 10.1016/j.jacc.2009.07.005

Di Sciascio, 2009, Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial, J Am Coll Cardiol, 54, 558, 10.1016/j.jacc.2009.05.028

Navarese, 2017, Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis, PLoS One, 12, e0168726, 10.1371/journal.pone.0168726

Amarenco, 2006, High-dose atorvastatin after stroke or transient ischemic attack, N Engl J Med, 355, 549, 10.1056/NEJMoa061894

Amarenco, 2009, Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention, Lancet Neurol, 8, 453, 10.1016/S1474-4422(09)70058-4

Merwick, 2013, Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment, Stroke, 44, 2814, 10.1161/STROKEAHA.113.001576

Flint, 2017, Statin adherence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation, Stroke, 48, 1788, 10.1161/STROKEAHA.117.017343

1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902

Kjekshus, 1997, The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease, J Card Fail, 3, 249, 10.1016/S1071-9164(97)90022-1

Khush, 2007, Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study, Circulation, 115, 576, 10.1161/CIRCULATIONAHA.106.625574

Kjekshus, 2007, Rosuvastatin in older patients with systolic heart failure, N Engl J Med, 357, 2248, 10.1056/NEJMoa0706201

Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401

Scirica, 2006, Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study, J Am Coll Cardiol, 47, 2326, 10.1016/j.jacc.2006.03.034

Preiss, 2015, The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials, Eur Heart J, 36, 1536, 10.1093/eurheartj/ehv072

Tavazzi, 2008, Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1231, 10.1016/S0140-6736(08)61240-4

Al-Gobari, 2017, No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials, PLoS One, 12, e0171168, 10.1371/journal.pone.0171168

Feinstein, 2015, Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF, Eur J Heart Fail, 17, 434, 10.1002/ejhf.247

Bayes-Genis, 2017, The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis, J Am Coll Cardiol, 70, 2128, 10.1016/j.jacc.2017.08.057

Francis, 2017, Cholesterol and heart failure: is there an important connection?, J Am Coll Cardiol, 70, 2137, 10.1016/j.jacc.2017.08.068

Tavazzi, 2008, Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1223, 10.1016/S0140-6736(08)61239-8

Smith, 2014, Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis, JAMA, 312, 1764, 10.1001/jama.2014.13959

Tsimikas, 2017, A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies, J Am Coll Cardiol, 69, 692, 10.1016/j.jacc.2016.11.042

Novaro, 2001, Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis, Circulation, 104, 2205, 10.1161/hc4301.098249

Chan, 2010, Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial, Circulation, 121, 306, 10.1161/CIRCULATIONAHA.109.900027

Cowell, 2005, A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis, N Engl J Med, 352, 2389, 10.1056/NEJMoa043876

Dichtl, 2008, Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg), Am J Cardiol, 102, 743, 10.1016/j.amjcard.2008.04.060

Thiago, 2016, Statins for aortic valve stenosis, Cochrane Database Syst Rev, 9, CD009571

Zhao, 2016, The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis, Atherosclerosis, 246, 318, 10.1016/j.atherosclerosis.2016.01.023

Greve, 2018, Effect modifications of lipid-lowering therapy on progression of aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study), Am J Cardiol, 121, 739, 10.1016/j.amjcard.2017.12.011

Arsenault, 2014, Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL), Am J Cardiol, 113, 1378, 10.1016/j.amjcard.2014.01.414

Huded, 2017, Relation of intensity of statin therapy and outcomes after transcatheter aortic valve replacement, Am J Cardiol, 119, 1832, 10.1016/j.amjcard.2017.02.042

Milin, 2014, Insights into aortic sclerosis and its relationship with coronary artery disease, J Am Heart Assoc, 3, e001111, 10.1161/JAHA.114.001111

Stevens, 2013, Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline, Ann Intern Med, 158, 825, 10.7326/0003-4819-158-11-201306040-00007

Franczyk-Skora, 2013, Acute coronary syndromes in patients with chronic kidney disease, Curr Vasc Pharmacol, 11, 758, 10.2174/1570161111311050013

Gansevoort, 2013, Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention, Lancet, 382, 339, 10.1016/S0140-6736(13)60595-4

Olechnowicz-Tietz, 2013, The risk of atherosclerosis in patients with chronic kidney disease, Int Urol Nephrol, 45, 1605, 10.1007/s11255-013-0407-1

Matsushita, 2010, Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis, Lancet, 375, 2073, 10.1016/S0140-6736(10)60674-5

Loncar, 2015, Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention, Arch Cardiovasc Dis, 108, 554, 10.1016/j.acvd.2015.06.001

Tonelli, 2014, Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline, Ann Intern Med, 160, 182, 10.7326/M13-2453

Barylski, 2013, Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants, Pharmacol Res, 72, 35, 10.1016/j.phrs.2013.03.007

Palmer, 2014, HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis, Cochrane Database Syst Rev, 5, CD007784

Agarwal, 2016, Post-transplant dyslipidemia: mechanisms, diagnosis and management, World J Transplant, 6, 125, 10.5500/wjt.v6.i1.125

Bamgbola, 2016, Metabolic consequences of modern immunosuppressive agents in solid organ transplantation, Ther Adv Endocrinol Metab, 7, 110, 10.1177/2042018816641580

Numakura, 2015, Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation, Dis Markers, 2015, 179434, 10.1155/2015/179434

Pinto, 2016, Dietary management for dyslipidemia in liver transplant recipients, Arq Bras Cir Dig, 29, 246, 10.1590/0102-6720201600040008

Riella, 2012, Dyslipidemia and its therapeutic challenges in renal transplantation, Am J Transplant, 12, 1975, 10.1111/j.1600-6143.2012.04084.x

Claes, 2012, Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study, Nephrol Dial Transplant, 27, 850, 10.1093/ndt/gfr238

Deleuze, 2006, New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?, Transplant Proc, 38, 2311, 10.1016/j.transproceed.2006.06.125

Kasiske, 2008, Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients, Am J Transplant, 8, 1384, 10.1111/j.1600-6143.2008.02272.x

Li, 2012, Higher tacrolimus blood concentration is related to hyperlipidemia in living donor liver transplantation recipients, Dig Dis Sci, 57, 204, 10.1007/s10620-011-1817-5

Morrisett, 2002, Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients, J Lipid Res, 43, 1170, 10.1194/jlr.M100392-JLR200

Page, 2005, Drug therapy in the heart transplant recipient: part IV: drug-drug interactions, Circulation, 111, 230, 10.1161/01.CIR.0000151805.86933.35

Almutairi, 2009, Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia, Liver Transpl, 15, 504, 10.1002/lt.21710

Shaw, 2009, The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin, Transplantation, 87, 771, 10.1097/TP.0b013e318198d7d0

Tendera, 2011, ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC), Eur Heart J, 32, 2851, 10.1093/eurheartj/ehr211

McDermott, 2003, Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease, Arch Intern Med, 163, 2157, 10.1001/archinte.163.18.2157

Aung, 2007, Lipid-lowering for peripheral arterial disease of the lower limb, Cochrane Database Syst Rev, 4, CD000123

Collins, 2003, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7

Bonaca, 2018, Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), Circulation, 137, 338, 10.1161/CIRCULATIONAHA.117.032235

Rajamani, 2009, Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial, Lancet, 373, 1780, 10.1016/S0140-6736(09)60698-X

Tedeschi-Reiner, 2005, Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease, Am J Cardiol, 96, 1107, 10.1016/j.amjcard.2005.05.070

Chew, 2010, Effects of medical therapies on retinopathy progression in type 2 diabetes, N Engl J Med, 363, 233, 10.1056/NEJMoa1001288

Keech, 2007, Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial, Lancet, 370, 1687, 10.1016/S0140-6736(07)61607-9

Golledge, 2006, Abdominal aortic aneurysm: pathogenesis and implications for management, Arterioscler Thromb Vasc Biol, 26, 2605, 10.1161/01.ATV.0000245819.32762.cb

Paraskevas, 2006, Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?, Eur J Vasc Endovasc Surg, 32, 286, 10.1016/j.ejvs.2006.03.009

Durazzo, 2004, Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial, J Vasc Surg, 39, 967, 10.1016/j.jvs.2004.01.004

Schouten, 2009, Fluvastatin and perioperative events in patients undergoing vascular surgery, N Engl J Med, 361, 980, 10.1056/NEJMoa0808207

Hackam, 2011, Statins and renovascular disease in the elderly: a population-based cohort study, Eur Heart J, 32, 598, 10.1093/eurheartj/ehq452

Subherwal, 2015, Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study, Eur J Prev Cardiol, 22, 317, 10.1177/2047487313519344

Ross, 1999, Atherosclerosis--an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207

Tabas, 2017, Monocyte-macrophages and T cells in atherosclerosis, Immunity, 47, 621, 10.1016/j.immuni.2017.09.008

Emini Veseli, 2017, Animal models of atherosclerosis, Eur J Pharmacol, 816, 3, 10.1016/j.ejphar.2017.05.010

Tillett, 1930, Serological reactions in pneumonia with a non-protein somatic fraction of Pneumococcus, J Exp Med, 52, 561, 10.1084/jem.52.4.561

Sabatine, 2007, Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease, Circulation, 115, 1528, 10.1161/CIRCULATIONAHA.106.649939

Ridker, 1997, Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, N Engl J Med, 336, 973, 10.1056/NEJM199704033361401

Ridker, 2000, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N Engl J Med, 342, 836, 10.1056/NEJM200003233421202

Danesh, 2004, C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N Engl J Med, 350, 1387, 10.1056/NEJMoa032804

Elliott, 2009, Genetic loci associated with C-reactive protein levels and risk of coronary heart disease, JAMA, 302, 37, 10.1001/jama.2009.954

Kaptoge, 2012, C-reactive protein, fibrinogen, and cardiovascular disease prediction, N Engl J Med, 367, 1310, 10.1056/NEJMoa1107477

Zacho, 2008, Genetically elevated C-reactive protein and ischemic vascular disease, N Engl J Med, 359, 1897, 10.1056/NEJMoa0707402

Miller, 2005, Association of common CRP gene variants with CRP levels and cardiovascular events, Ann Hum Genet, 69, 623, 10.1111/j.1529-8817.2005.00210.x

Koenig, 2013, High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy, Int J Cardiol, 168, 5126, 10.1016/j.ijcard.2013.07.113

Grundy, 2018, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, S0735

Arnaud, 2005, Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins, Arterioscler Thromb Vasc Biol, 25, 1231, 10.1161/01.ATV.0000163840.63685.0c

Bohula, 2015, Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT, Circulation, 132, 1224, 10.1161/CIRCULATIONAHA.115.018381

Ridker, 2005, C-reactive protein levels and outcomes after statin therapy, N Engl J Med, 352, 20, 10.1056/NEJMoa042378

Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646

Ridker, 2001, Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N Engl J Med, 344, 1959, 10.1056/NEJM200106283442601

Ridker, 1998, Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators, Circulation, 98, 839, 10.1161/01.CIR.98.9.839

Ridker, 2009, Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial, Lancet, 373, 1175, 10.1016/S0140-6736(09)60447-5

Barbosa, 2013, Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein, Life Sci, 92, 845, 10.1016/j.lfs.2013.02.018

Sahebkar, 2016, Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms, Br J Clin Pharmacol, 81, 1175, 10.1111/bcp.12905

Ridker, 2017, Antiinflammatory therapy with canakinumab for atherosclerotic disease, N Engl J Med, 377, 1119, 10.1056/NEJMoa1707914

Ridker, 2009, Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT), J Thromb Haemost, 7, 332, 10.1111/j.1538-7836.2009.03404.x

Ridker, 2019, Low-dose methotrexate for the prevention of atherosclerotic events, N Engl J Med, 380, 752, 10.1056/NEJMoa1809798

Weber, 2017, Therapeutic strategies for atherosclerosis and atherothrombosis: past, present and future, Thromb Haemost, 117, 1258, 10.1160/TH16-10-0814

Newman, 2006, Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients, Am J Cardiol, 97, 61, 10.1016/j.amjcard.2005.07.108

Bays, 2014, The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update, J Clin Lipidol, 8, S47, 10.1016/j.jacl.2014.02.011

Bjornsson, 2012, Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing, J Hepatol, 56, 374, 10.1016/j.jhep.2011.07.023

Clarke, 2016, High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort, PLoS One, 11, e0151587, 10.1371/journal.pone.0151587

Cederberg, 2015, Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort, Diabetologia, 58, 1109, 10.1007/s00125-015-3528-5

Mora, 2010, Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials, Circulation, 121, 1069, 10.1161/CIRCULATIONAHA.109.906479

Timmis, 2018, European Society of Cardiology: cardiovascular disease statistics 2017, Eur Heart J, 39, 508, 10.1093/eurheartj/ehx628

Roth, 2015, Demographic and epidemiologic drivers of global cardiovascular mortality, N Engl J Med, 372, 1333, 10.1056/NEJMoa1406656

Aspelund, 2010, Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006, PLoS One, 5, e13957, 10.1371/journal.pone.0013957

Bjorck, 2009, Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002, Eur Heart J, 30, 1046, 10.1093/eurheartj/ehn554

Pereira, 2013, Explaining the decline in coronary heart disease mortality in Portugal between 1995 and 2008, Circ Cardiovasc Qual Outcomes, 6, 634, 10.1161/CIRCOUTCOMES.113.000264

Unal, 2013, Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008, BMC Public Health, 13, 1135, 10.1186/1471-2458-13-1135

EunetHta Joint Action, 2016, Is there a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries, Pharmacoeconomics, 34, 59, 10.1007/s40273-015-0328-1

Drummond, 2009, Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report, Value Health, 12, 409, 10.1111/j.1524-4733.2008.00489.x

Frieden, 2010, A framework for public health action: the health impact pyramid, Am J Public Health, 100, 590, 10.2105/AJPH.2009.185652

Hotchkiss, 2014, Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data, BMJ, 348, g1088, 10.1136/bmj.g1088

Cobiac, 2012, Which interventions offer best value for money in primary prevention of cardiovascular disease?, PLoS One, 7, e41842, 10.1371/journal.pone.0041842

Collins, 2014, An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study, Value Health, 17, 517, 10.1016/j.jval.2014.03.1722

Mason, 2014, A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries, PLoS One, 9, e84445, 10.1371/journal.pone.0084445

Moreira, 2015, Comparing different policy scenarios to reduce the consumption of ultra-processed foods in UK: impact on cardiovascular disease mortality using a modelling approach, PLoS One, 10, e0118353, 10.1371/journal.pone.0118353

O'Keeffe, 2013, Modelling the impact of specific food policy options on coronary heart disease and stroke deaths in Ireland, BMJ Open, 3, e002837, 10.1136/bmjopen-2013-002837

Barton, 2011, Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study, BMJ, 343, d4044, 10.1136/bmj.d4044

Muennig, 2014, The cost-effectiveness of New York City's Safe Routes to School Program, Am J Public Health, 104, 1294, 10.2105/AJPH.2014.301868

Roux, 2008, Cost effectiveness of community-based physical activity interventions, Am J Prev Med, 35, 578, 10.1016/j.amepre.2008.06.040

Jørgensen, 2013, Population-level changes to promote cardiovascular health, Eur J Prev Cardiol, 20, 409, 10.1177/2047487312441726

Mozaffarian, 2011, Components of a cardioprotective diet: new insights, Circulation, 123, 2870, 10.1161/CIRCULATIONAHA.110.968735

Dalziel, 2007, Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions, Health Promot Int, 22, 271, 10.1093/heapro/dam027

Ahern, 2017, Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial, Lancet, 389, 2214, 10.1016/S0140-6736(17)30647-5

Neumann, 2017, The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program, Eur J Health Econ, 18, 905, 10.1007/s10198-016-0851-9

Hoogendoorn, 2010, Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD, Thorax, 65, 711, 10.1136/thx.2009.131631

Forster, 2011, Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity, Int J Obes (Lond), 35, 1071, 10.1038/ijo.2010.246

Chow, 2010, Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes, Circulation, 121, 750, 10.1161/CIRCULATIONAHA.109.891523

Loveman, 2011, The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review, Health Technol Assess, 15, 1, 10.3310/hta15020

Guerriero, 2013, The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop, Eur J Health Econ, 14, 789, 10.1007/s10198-012-0424-5

McConnachie, 2014, Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study, Eur Heart J, 35, 290, 10.1093/eurheartj/eht232

Peura, 2008, Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men, Curr Med Res Opin, 24, 1823, 10.1185/03007990802144705

Heller, 2017, Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke, Circulation, 136, 1087, 10.1161/CIRCULATIONAHA.117.027067

Pandya, 2015, Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease, JAMA, 314, 142, 10.1001/jama.2015.6822

Mihaylova, 2006, Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people, BMJ, 333, 1145, 10.1136/bmj.38993.731725.BE

Ward, 2007, A systematic review and economic evaluation of statins for the prevention of coronary events, Health Technol Assess, 11, 1, 10.3310/hta11140

Davies, 2017, Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States, J Med Econ, 20, 723

Lindgren, 2007, Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin, Eur Heart J, 28, 1448, 10.1093/eurheartj/ehm020

Stam-Slob, 2017, Cost-effectiveness of intensifying lipid-lowering therapy with statins based on individual absolute benefit in coronary artery disease patients, J Am Heart Assoc, 6, e004648, 10.1161/JAHA.116.004648

Kotseva, 2016, On Behalf Of The Euroaspire Investigators. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions, Eur J Prev Cardiol, 23, 2007, 10.1177/2047487316667784

Cherry, 2009, The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients, Value Health, 12, 489, 10.1111/j.1524-4733.2008.00447.x

Vonbank, 2017, Comprehensive efforts to increase adherence to statin therapy, Eur Heart J, 38, 2473

Corrao, 2011, Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases, Atherosclerosis, 217, 479, 10.1016/j.atherosclerosis.2011.04.014

Chapman, 2010, The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications, Value Health, 13, 685, 10.1111/j.1524-4733.2010.00774.x

Brown, 2011, Medication adherence: WHO cares?, Mayo Clin Proc, 86, 304, 10.4065/mcp.2010.0575

Bonow, 2017, Cost-effectiveness of PCSK9 inhibitors: proof in the modeling, JAMA Cardiol, 2, 1298, 10.1001/jamacardio.2017.3656

Arrieta, 2017, Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial, JAMA Cardiol, 2, 1369, 10.1001/jamacardio.2017.3655

Fonarow, 2017, Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease, JAMA Cardiol, 2, 1069, 10.1001/jamacardio.2017.2762

Korman, 2018, Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting, Eur Heart J Cardiovasc Pharmacother, 4, 15, 10.1093/ehjcvp/pvx010

Annemans, 2018, ‘Highest risk-highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies, Eur Heart J, 39, 2546, 10.1093/eurheartj/ehx710

Robinson, 2016, Determining when to add nonstatin therapy: a quantitative approach, J Am Coll Cardiol, 68, 2412, 10.1016/j.jacc.2016.09.928

Kazi, 2017, Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial, JAMA, 318, 748, 10.1001/jama.2017.9924

Wood, 2008, EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial, Lancet, 371, 1999, 10.1016/S0140-6736(08)60868-5